Johnson & Johnson will present new clinical and real-world data on its TECNIS PureSee intraocular lens (IOL) at the 2026 ASCRS Annual Meeting in Washington, DC, adding to the evidence base for the recently FDA-approved extended depth of focus (EDOF) lens.
The TECNIS PureSee is a purely refractive EDOF IOL designed to extend range of vision beyond that of a standard monofocal lens while maintaining contrast sensitivity. Data presented at the meeting span a prospective, randomized US clinical trial and a large post-market observational study conducted across Europe and Asia-Pacific.
Randomized trial data
Results from a US study of more than 200 patients across nine sites suggest the lens delivers strong distance vision alongside improved intermediate performance compared with a monofocal control (TECNIS 1-piece IOL). Investigators also report some gains in near vision, with contrast sensitivity comparable to an aspheric monofocal lens.
Across the datasets presented:
Distance-corrected intermediate vision reached a mean of 20/28 (monocular)
Patients gained approximately 1.5 lines of near vision versus control
Visual disturbance rates were reported as low
Performance appeared independent of pupil size
A separate analysis examining refractive error tolerance found that 94 percent of patients maintained distance-corrected visual acuity of 20/25 or better within ±0.5 D defocus. Patient-reported outcomes indicated high levels of satisfaction, with most participants reporting little or no need for distance spectacles.
Real-world evidence
Additional findings from a post-market study involving more than 700 patients across 19 sites reinforce these results in routine clinical settings.
Reported outcomes include:
Mean binocular uncorrected distance vision of approximately 20/19
Intermediate vision around 20/26
High rates of spectacle independence for distance (96 percent) and intermediate (95 percent), with lower rates for near (61 percent)
Patient satisfaction exceeding 90 percent
Visual symptoms such as glare, halos and starbursts were reported as infrequent, with more than 90 percent of patients describing little or no disturbance. The lens also demonstrated tolerance to residual postoperative refractive error in subgroup analyses.
Broader TECNIS portfolio data
Johnson & Johnson will also present additional data across its TECNIS platform. Findings include reports of high spectacle independence and low rates of severe dysphotopsia with the TECNIS Odyssey IOL, as well as early data suggesting no measurable endothelial cell loss with the VERITAS Vision System.
At the meeting
The company will showcase these data alongside educational sessions and technology demonstrations at ASCRS (booth #625), including simulated visual outcomes and hands-on system demonstrations.
